Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: J Hepatol. 2023 Jun 20;79(4):1025–1036. doi: 10.1016/j.jhep.2023.05.045

Fig. 6. Blocking neutrophil recruitment by CXCR1/2 inhibitor reduces biliary epithelium expansion in chronic injury.

Fig. 6.

(A) Mice were fed with DDC and treated daily with CXCR1/2 inhibitor (SCH-527123) for 3 weeks at a dose of 50 mg/kg. (B) Immunohistochemistry analysis of liver sections of control and 3-weeks DDC-fed mice treated with SCH-527123 or vehicle (n = 5–6 mice per group). Scale bars: 100 μm. (C) Immunofluorescence of progenitor markers in liver sections of mice fed with DDC for 3 weeks and treated with SCH-527123 inhibitor or vehicle. Scale bars: 100 μm. (D) Immunofluorescence of KRT19 and CCND1 in mice treated with SCH-527123 or vehicle (n = 3–5 mice per group). Scale bars: 50 μm. Data presented as mean ± SEM. *p <0.05, **p <0.01 and ***p <0.001 as determined by one-way ANOVA with Tukey’s multiple comparison test (B) and Student’s t test (D). CCND1, cyclin D1; CD31, cluster of differentiation 31; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; EpCAM, epithelial cell adhesion molecule; KRT, cytokeratin; MPO, myeloperoxidase; SOX9, SRY-Box transcription factor 9; S/R, sirius red; Veh, vehicle; wk, weeks.